Module 2: How to Customize the Screening Funnel for Safety Assessment

Recorded On: 03/19/2026

image
image


Clinical stage attrition is detrimental to patients and expensive for the pharmaceutical industry. In the past decade, effort has been made to develop, define, and implement a drug discovery toxicology paradigm to deliver the best development candidates by failing early and cheap unfavorable compounds. The drug discovery process involves a multistep toxicology screening funnel that filters potential drug candidates through increasingly complex and costly stages—starting with thousands of compounds and narrowing down to one approved drug. It begins with in silico (computer-based) screening to predict activity and toxicity, followed by in vitro (cell-based) high-throughput assays for basic toxic effects. Compounds that pass move on to more advanced in vitro testing. In the later preclinical stage, in vivo (animal) testing and safety pharmacology evaluate effects on organ systems. This funnel approach improves cost and time efficiency, allows for early risk identification, optimizes resources, and integrates various testing methods to build a comprehensive safety profile for drug candidates.

Yvonne Will, PhD, ATS

Yvonne Will, PhD, ATS

Consultant

SCIENTIA-Consultants LLC

Dr. Yvonne Will is an independent consultant specializing in nonclinical drug safety, discovery toxicology, and the strategic application of new approach methodologies (NAMs) to support decision-making and regulatory readiness in drug development. Through her consulting practice, SCIENTIA-Consultants LLC, she advises biotechnology and pharmaceutical companies on predictive safety strategies, mechanistic toxicology, and fit-for-purpose nonclinical programs from early discovery through IND/CTA-enabling stages.

Dr. Will brings more than two decades of experience in global pharmaceutical R&D, having previously held senior leadership roles including Vice President of Nonclinical Drug Safety and Toxicology at Crinetics Pharmaceuticals, Global Science and Technology Lead for Drug Safety at Pfizer, and senior positions in predictive and investigative toxicology at Janssen (Johnson & Johnson). Across these roles, she has led multidisciplinary teams, shaped nonclinical safety strategy, and advanced the integration of human-relevant in vitro and mechanistic models into discovery and development workflows.

Her scientific expertise spans mitochondrial toxicity, liver safety, cardiovascular risk assessment, mechanistic toxicology, and the design of tiered screening funnels that integrate NAMs within a regulatory-aligned weight-of-evidence framework. Dr. Will is widely recognized for her thought leadership in modernizing toxicology and bridging the gap between cutting-edge science and regulatory expectations.

Dr. Will is actively engaged in the toxicology community and has served in leadership roles within the Society of Toxicology, including as President of the Drug Discovery Specialty Section. She has contributed extensively to the scientific literature and serves on editorial boards for journals focused on applied and translational toxicology.

She holds a PhD and MS in Biochemistry and Biophysics from Oregon State University and a BS from the University of Bonn.

Key:

Complete
Failed
Available
Locked
Module 2 How to Customize the Screening Funnel for Safety Assessment
Module 2: How to Customize the Screening Funnel for Safety Assessment, Yvonne Will, PhD, ATS
Recorded 03/19/2026  |  90 minutes
Recorded 03/19/2026  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.